|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.23 - 2.30|
|52 Week Range||2.21 - 8.77|
|PE Ratio (TTM)||-34.84|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
The much smaller asset purchase they are now attempting should not raise the kinds of concerns the commission had about the original merger, they argue.
For several reasons, Rite Aid now has the right prescription to heal the tough wounds investors have suffered over the past several years. The company’s valuation, currently at $2.4 billion, is a fraction of the $8.5 billion it was valued at in January when it had an offer on the table from Walgreens of $6.50 to $7.00 per share. This is even though both Rite Aid and Walgreens agreed to divest several stores to Fred’s, Inc. (NASDAQ:FRED) to make the deal more palatable.